didemethylchlorpromazine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 74981 |
| CHEMBL ID | 824 |
| CHEBI ID | 125636 |
| SCHEMBL ID | 11202527 |
| MeSH ID | M0079532 |
| Synonym |
|---|
| cpzsl |
| cl-ppa |
| uws2ta46b8 , |
| didesmethylchlorpromazine |
| gamma-(2-chlorophenothiazinyl-10)-propylamine |
| 2-chloro-10h-phenothazine-10-propanamine |
| 2095-17-2 |
| unii-uws2ta46b8 |
| phenothiazine, 10-(3'-aminopropyl)-2-chloro- |
| 10-(3-aminopropyl)-2-chloro-10h-phenothiazine, maleate |
| 3-(2-chloro-10h-phenothiazin-10-yl)-1-propanamine, maleate |
| nsc168977 |
| 3-(2-chloro-10h-phenothiazin-10-yl)propylamine, maleate |
| 3-(2-chlorophenothiazin-10-yl)propan-1-amine |
| 10h-phenothiazine-10-propanamine, 2-chloro-, maleate |
| NCI60_001350 |
| didemethylchlorpromazine |
| CHEBI:125636 |
| CHEMBL824 , |
| nor2-chlorpromazine |
| 2-chloro-10-(3-aminopropyl)phenothiazine |
| 3-(2-chloro-10h-phenothiazin-10-yl)propan-1-amine |
| 3-(2-chloro-phenothiazin-10-yl)-propylamine |
| bdbm50339134 |
| BRD-K78075916-001-01-5 |
| AKOS025243291 |
| SCHEMBL11202527 |
| didesmethyl chlorpromazine |
| 2-chloro-10h-phenothiazine-10-propanamine |
| Q27216248 |
| 3-(2-chloro-10-phenothiazinyl)-1-propanamine |
| DTXSID00175126 |
| 2-chloro-10-(3-amino-propyl) phenothiazine |
| dedimethylchlorpromazine |
| 10h-phenothiazine-10-propanamine, 2-chloro- |
| nor2-cpz |
| cp-38889 |
| nor2chlorpromazine |
| m-942 |
| di-n-demethyl-chlorpromazine |
| phenothiazine, 10-(3-aminopropyl)-2-chloro- |
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Trypanothione reductase | Trypanosoma cruzi | IC50 (µMol) | 139.0000 | 5.8000 | 5.8000 | 5.8000 | AID214488 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | IC50 (µMol) | 3.2000 | 1.3000 | 3.3727 | 9.6000 | AID581672 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Snq2p | Saccharomyces cerevisiae EC1118 | INH | 5.8000 | 3.2000 | 6.2600 | 8.8000 | AID581808 |
| Pleiotropic ABC efflux transporter of multiple drugs | Saccharomyces cerevisiae S288C | INH | 4.2000 | 4.2000 | 6.1833 | 8.3000 | AID581806 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1247112 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 50 mM K+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 50 mM K+ | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID1247110 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of H+ at pH 6.4 to 8.2 to IC50 for NMDA receptor in Wistar rat brain membranes in absence of H+ at pH 6.4 to 8.2 | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID581807 | Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID1247108 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 30 uM spermine to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 30 uM spermine | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID581806 | Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID1247113 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 20 mM NH4+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 20 mM NH4+ | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID1247109 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 10 to 50 mM Tris to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 10 to 50 mM Tris | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID1247111 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 3 to 50 mM Na+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 3 to 50 mM Na+ | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID1247107 | Displacement of [3H]MK-801 from NMDA receptor in Wistar rat brain membranes by scintillation counting analysis | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID1247114 | Ratio of IC50 for NMDA receptor in Wistar rat brain membranes in presence of 1.3 mM Mg2+ to IC50 for NMDA receptor in Wistar rat brain membranes in absence of 1.3 mM Mg2+ | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers. |
| AID581808 | Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID140479 | Effective dose against Trypanosoma cruzi (Trypanosoma cruzi) trypomastigotes in mouse peritoneal macrophages | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. |
| AID581672 | Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. |
| AID103232 | Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX | 1998 | Journal of medicinal chemistry, May-21, Volume: 41, Issue:11 | Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. |
| AID214488 | Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. |
| AID75299 | Inhibitory activity against human erythrocyte glutathione reductase; '*' indicates No inhibition | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. |
| AID140478 | Effective dose against Trypanosoma brucei) trypomastigotes in mouse peritoneal macrophages; <3, >1 | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. |
| AID140476 | Effective dose against Leishmania donovani (Leishmania donovani) amastigotes in mouse peritoneal macrophages | 1998 | Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2 | Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||